Skip to main content
Clinical Trials/NL-OMON53227
NL-OMON53227RecruitingNot Applicable

The effect of total knee replacement surgery on immune functioning in elderly - Immu-KNEE-ty

Wageningen Universiteit0 sites14 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
14

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
65 to 99 (—)

Inclusion Criteria

  • - Planned for primary total knee replacement surgery
  • - Aged 65 years or over
  • - Diagnosed with osteoarthritis
  • - ASA Physical Status Classification of II or III
  • - Scheduled for general anesthesia
  • - Willing to donate a blood sample at 5 different timepoints
  • - Able to give written informed consent

Exclusion Criteria

  • - Daily use of high doses NSAIDs within the 14 days before inclusion: Defined as higher than maintenance dose in the *farmacotherapeutisch kompas*. For example: acetylsalicylic acid > 4 g /day; diclofenac > 75 mg/day; naproxen > 500 mg/day; ibuprofen> 1600 mg/day; celecoxib > 200 mg/day - Use of systemic corticosteroids - Use of antibiotics within the 14 days before inclusion - Current diagnosis of cancer - Diagnosed with a primary immunodeficiency disorder (e.g., Severe Combined Immunodeficiency (SCID), Common Variable Immune Deficiency (CVID), X-linked agammaglobulinemia, selective immunoglobulin A deficiency, chronic granulomatous disease) - Vaccination (e.g., immunization against COVID-19, influenza, pneumonia, and travel-related infections) within the 14 days before inclusion and during the study period - Current participation in other scientific research

Investigators

Similar Trials